Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples